Clinical Trial Update: The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis

View source ↗

Summary

This document describes a completed clinical trial evaluating the role of the FGL2-FcgammaRIIB inhibitory pathway in chronic hepatitis C infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Snippet

Sponsor: University Health Network, Toronto | Conditions: Chronic Hepatitis C Infection | Status: COMPLETED